ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2808

Genetic Variants at Chromosome 5q15 Associated with Immune-Mediated Diseases Influence Gene Expression and Isoform Profile of the Endoplasmic Reticulum Aminopeptidase

Aimee Hanson1, Katelin Haynes2, Gethin Thomas2, Thomas Cuddihy2, Paul Leo2 and Matthew A. Brown1, 1The University of Queensland Diamantina Institute, Brisbane, Australia, 2University of Queensland Diamantina Institute, Brisbane, Australia

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Ankylosing spondylitis (AS) and genetics, Gene Expression

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology Poster I

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Polymorphisms in the endoplasmic reticulum aminopeptidase genes ERAP1 and/or ERAP2 are strongly associated with the diseases AS, psoriasis, IBD and Behcet’s disease. Robust genetic interaction exists between ERAP1 and the HLA Class I alleles HLA-B27 and –B40 (associated with AS), -Cw6 (in psoriasis), and -B*51 (in Behcet’s disease).  In AS, two ERAP1 haplotypes are disease associated, tagged either by rs30187 (thought to be directly disease-associated) or rs10050860 (which lies on a disease-associated haplotype). Protective alleles of rs30187 are associated with reduced peptidase activity. We hypothesized that other AS-associated ERAP1 and ERAP2 genetic variants would also either lead to reduced function or expression of the respective gene.

Methods: RNA sequencing was performed on PBMC derived total RNA from 54 AS cases and 70 healthy controls. This data was analysed to investigate the gene and isoform expression profiles of ERAP1 and ERAP2. The consequences of ERAP1 variants on the protein level were then validated by mass spectrometry.

Results: Considering markers in linkage disequilibrium with rs30187, multiple showed effects on expression of ERAP1 (P=5.27×10-7 for lead variant rs39840), with protective variants invariably leading to reduced ERAP1 expression. The same property was noted for multiple protective ERAP2 variants associated with ERAP2 expression (lead SNP rs2910686, P=1.71×10-6, after correction for rs2248374 which leads to nonsense mediated decay of ERAP2 transcripts). On the second ERAP1 haplotype tagged by the SNP rs10050860, a subset of variants alter the expression of two isoforms of the gene. The risk allele at the lead putative splice altering polymorphism, rs7063, correlated with a significant increase in expression of the canonical 19-exon ERAP1 isoform (P=8.7×10-12, expression level 2x greater in AS-risk genotype carriers), and a significant decrease in the expression of a second 20-exon isoform (P=1.0×10-17, expression level 0.47x lower in risk genotype carriers). The proportion of the 19-exon isoform was also significantly greater in cases than controls (P=0.047). The correlation between ERAP1 disease risk genotype and isoform profile was replicated at the protein level. Protein expression of the second isoform was greatly reduced, rendering individual carrying the protective genotype at rs7063, with predominant production of this transcript variant, with significantly less total ERAP1 overall (P =1.58×10-6).

Conclusion: ERAP1 and ERAP2 genetic variants operate by effects on protein function, expression and sequence to influence the risk of developing AS and related diseases.


Disclosure: A. Hanson, None; K. Haynes, None; G. Thomas, None; T. Cuddihy, None; P. Leo, None; M. A. Brown, Abbvie, Pfizer, UCB, Wyeth, Leo Pharma, NIAMS, NHMRC, Arthritis Australia, Qld Government, 2,Pfizer, Abbvie, UCB, 5,Pfizer, Abbvie, UCB, 8.

To cite this abstract in AMA style:

Hanson A, Haynes K, Thomas G, Cuddihy T, Leo P, Brown MA. Genetic Variants at Chromosome 5q15 Associated with Immune-Mediated Diseases Influence Gene Expression and Isoform Profile of the Endoplasmic Reticulum Aminopeptidase [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/genetic-variants-at-chromosome-5q15-associated-with-immune-mediated-diseases-influence-gene-expression-and-isoform-profile-of-the-endoplasmic-reticulum-aminopeptidase/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-variants-at-chromosome-5q15-associated-with-immune-mediated-diseases-influence-gene-expression-and-isoform-profile-of-the-endoplasmic-reticulum-aminopeptidase/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology